Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Clinical Trial
Official title:
A Groupwide Biology and Banking Study for Ewing Sarcoma
Diagnostic trial to study genetic differences in patients who have Ewing's sarcoma. Genetic testing may help predict how cancer will respond to treatment and allow doctors to plan more effective therapy.
PRIMARY OBJECTIVES:
I. To develop a mechanism to collect and distribute tumor specimens to various
investigators, and a system to prioritize and develop quality-control measures for central
data reporting of studies undertaken.
II. To determine the prognostic significance of translocation subtype in Ewing sarcoma; to
determine the prognostic significance of translocation negative Ewing sarcoma.
III. To determine the prognostic significance of MRD detection in bone marrow specimens by
RT-PCR determination of EWS-ETS fusion genes.
IV. To determine whether serum levels of IGF1, IGFBP3 are of significance in the outcome of
patients with Ewing sarcoma.
V. To determine whether RNA expression profiles performed on diagnostic specimens will allow
for the identification of newer prognostic categories and potentially new molecular targets
for treatment in Ewing sarcoma.
VI. To identify new treatment targets for therapy. Further testing of these potential
targets will be carried out in hopes of expediting translation of these findings to the
clinic.
VII. To establish a bank of Ewing sarcoma xenografts in SCID/Beige mice. VIII. To establish
clinical proteomics as a resource for investigations of altered signaling molecules in the
pathogenesis of Ewing sarcoma.
OUTLINE: This is a multicenter study.
Patients undergo various specimen collections, including bone marrow aspirate,
paraffin-embedded blocks of tumor tissue or slides of tumor tissue, and blood specimens.
These specimens are collected before, during, and after any chemotherapy regimens, during
follow-up, and at time of recurrence. Translocation studies are performed on specimens to
identify fusion genes, specifically EWS-ETS. Serum IGF1 and IFGBP3 levels are determined.
Bone marrow is assessed for minimal residual disease using reverse-transcriptase polymerase
chain reaction.
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00093821 -
Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
| Completed |
NCT00004078 -
Irinotecan in Treating Children With Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT00004241 -
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
|
Phase 1 | |
| Completed |
NCT00030667 -
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
|
Phase 2 | |
| Completed |
NCT02116777 -
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT02304458 -
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
|
Phase 1/Phase 2 | |
| Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
| Active, not recruiting |
NCT03210714 -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Withdrawn |
NCT02011126 -
Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT00536601 -
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
|
N/A | |
| Completed |
NCT01154452 -
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00330421 -
Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)
|
Phase 2 | |
| Completed |
NCT01614795 -
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
|
Phase 2 | |
| Withdrawn |
NCT01795430 -
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
|
N/A | |
| Completed |
NCT00609141 -
IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor
|
Phase 1 | |
| Active, not recruiting |
NCT00112463 -
Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
| Completed |
NCT00899990 -
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma
|
||
| Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 |